Heart Failure
Conditions
Brief summary
LCZ696, a molecular complex of the angiotensin receptor blocker (ARB) valsartan with an inhibitor of neprilysin (NEP, neutral endopeptidase-24.11) sacubitril improved mortality compared to enalapril in patients with heart failure (HF), reduced ejection fraction (EF), and increased brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) in the PARADIGM-HF trial.1 The PIONEER-HF study demonstrated the efficacy of LCZ696 in preventing rehospitalization in patients with acutely decompensated HF.2 LCZ696 has been underutilized in heart failure, in part due to concerns about hypotension. NEP degrades several vasodilator peptides including bradykinin, substance P and brain-type natriuretic peptide. Decreased degradation of endogenous bradykinin could contribute to hypotension at initiation of LCZ696 through vasodilation or through increased natriuresis and diuresis. Inhibition of the bradykinin B2 receptor using icatibant would be expected to prevent this effect. Objectives The main objectives of this mechanistic randomized, double-blind, crossover-design study are: * The primary objective is to test the hypothesis that endogenous bradykinin contributes to effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis at initiation. * The secondary objective is to test the hypothesis endogenous bradykinin contributes to effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis after up-titration. Eighty (80) subjects with stable heart failure who meet all inclusion/exclusion criteria will be enrolled. Subjects who qualify will collect their urine for 24 hours before each study day for measurement of volume, sodium and potassium. At the start of the study, they will stop their regular angiotensin-converting enzyme (ACE) inhibitor or ARB. After a 48-hour washout, they will undergo a study day in which they are given a single dose of 50 mg LCZ696. They will also receive either the bradykinin B2 receptor antagonist icatibant or placebo vehicle in random order (double-blind). After a 96-hour washout, they will repeat the study day and receive a single dose of 50 mg LCZ696 and the opposite study drug (icatibant or placebo). After completion of the two acute study days, subjects will take LCZ696 50 mg bid for two weeks, followed by LCZ696 100 mg bid for three weeks, and then LCZ696 200 mg bid, following the conservative up-titration protocol from the TITRATION study.3 Criteria for continuing up-titration appear in the full study protocol. On the 7th and 10th day of the 200 mg bid or highest tolerated dose, subjects will again undergo two more study days three days apart in which they are randomized to receive either icatibant or vehicle.
Interventions
DRUGLCZ 696
Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
DRUGIcatibant
Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
DRUGplacebo
Placebo (vehicle) will be given at the same rate as icatibant.
Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
DRUGIohexol
Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
Sponsors
Vanderbilt University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Black and white men and women 2. Stable patients with a reduced ejection fraction (EF) 1. EF ≤40%, and 2. history of symptoms of New York Heart Association (NYHA) class I, II, or III heart failure (HF) 3. stable clinical symptoms including no hospitalizations for the last six months 4. who are not already taking LCZ696 3. treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and with a beta blocker (unless contraindicated or not tolerated) for at least four weeks 4. for patients with NYHA Class II or III HF, treatment with a stable dose of an mineralocorticoid receptor (MR) antagonist for at least four weeks, unless not possible due to renal function or serum potassium. 5. For female subjects, the following conditions must be met: 1. postmenopausal status for at least one year, or 2. status post-surgical sterilization 3. or if of childbearing potential, utilization of barrier methods of birth control or an oral contraceptive and willingness to undergo urine β- human chorionic gonadotropin (HCG) testing on every study day
Exclusion criteria
1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEi, ARBs, or neutral endopeptidase inhibitor (NEPi), as well as known or suspected contraindications to the study drugs 2. History of angioedema 3. History of decompensated HF within the last three months (exacerbation of chronic HF manifested by signs and symptoms that required intravenous therapy or hospitalization) 4. History of heart transplant or on a transplant list or with left ventricular assistance device 5. Symptomatic hypotension and/or a systolic blood pressure (SBP)\<100 mmHg at screening or \<95 mmHg during the study 6. Serum potassium \>5.2 mmol/L at screening or \>5.4 mmol/L during the study 7. Impaired renal function (eGFR of \<30mL/min/1.73 m2) as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in years: eGFR (mL/min/1.73 m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if female) 8. Acute coronary syndrome, cardiac, carotid, or other major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty within six months prior to screening 9. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months of screening 10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack 11. History of ventricular arrhythmia with syncopal episodes 12. Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker 13. Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricle (LV) dilatation 14. Presence of other hemodynamically significant obstructive lesions of the LV outflow tract, including aortic and subaortic stenosis 15. Type 1 diabetes 16. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c \>9% 17. In T2DM, dipeptidyl peptidase-4 inhibitor use for one month prior to enrollment will be excluded due to possible interaction with LCZ696 18. Hematocrit \<35% 19. Breast feeding and pregnancy 20. History or presence of immunological or hematological disorders 21. History of malignancy not felt to be cured, except non-melanoma skin cancer 22. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week 23. History of hypersensitivity reaction to contrast 24. Clinically significant gastrointestinal impairment that could interfere with drug absorption 25. History of pancreatitis or known pancreatic lesions 26. Impaired hepatic function \[aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) \>3.0 x upper limit of normal range\] 27. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal anti-inflammatory drugs 28. Treatment with chronic systemic glucocorticoid therapy within the last year 29. Treatment with lithium salts 30. History of alcohol or drug abuse 31. Treatment with any investigational drug in the one month preceding the study 32. Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study 33. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Arterial Pressure | Eight hours | Mean arterial pressure (MAP) will be measured before and after administration of LCZ696 on each of the four study days. |
| Urine Sodium Excretion | Total urine output from drug administration to six hours following drug administration | Urine sodium excretion will be measured for six hours following study LCZ696 on each of the four study days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart Rate | Over six hours on each of four study days | Heart rate (HR) will be measured before and after LCZ696 on each of the four study days. |
| Urine Volume | Over six hours on each of four study days | Urine volume will be measured for six hours following LCZ696 on each of the four study days. |
| Renal Plasma Flow | Over six hours on each of four study days | Renal plasma flow (RPF) will be calculated from para-aminohippurate clearance prior to and following LCZ696. |
| Glomerular Filtration Rate | Over six hours on each of four study days | Glomerular filtration rate (GFR) will be calculated from the clearance of iohexol prior to and following LCZ66 on each of the four study days. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORNancy J. Brown, M.D.
Vanderbilt University Medical Center
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 61.0 years STANDARD_DEVIATION 11.2 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 25 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 36 | 0 / 36 | 0 / 33 | 0 / 31 | 0 / 30 |
| other Total, other adverse events | 3 / 36 | 2 / 36 | 4 / 33 | 0 / 31 | 0 / 30 |
| serious Total, serious adverse events | 0 / 36 | 0 / 36 | 0 / 33 | 0 / 31 | 0 / 30 |
Outcome results
None listed